Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C


Kose Ş., Senger S. S., Ersan G., Cavdar G.

CLINICAL AND EXPERIMENTAL NEPHROLOGY, vol.17, no.1, pp.115-119, 2013 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 1
  • Publication Date: 2013
  • Doi Number: 10.1007/s10157-012-0663-x
  • Journal Name: CLINICAL AND EXPERIMENTAL NEPHROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.115-119
  • Keywords: Hepatitis C, Interferon, Hemodialysis patients, STAGE RENAL-DISEASE, VIRUS-INFECTION, DIALYSIS PATIENTS, VIRAL-HEPATITIS, EFFICACY, RIBAVIRIN, MANAGEMENT, PEGYLATED-INTERFERON-ALPHA-2A, TRANSPLANTATION, METAANALYSIS
  • Dokuz Eylül University Affiliated: No

Abstract

Hepatitis C is the most frequently encountered hepatic disease in dialysis patients. Data related to pegylated interferon alfa-2a (Peg-IFN-alpha-2a) use in hemodialysis patients with hepatitis C virus (HCV) are limited. The aim of this study was to evaluate the efficacy of Peg-IFN-alpha-2a among these patients.